Lv2
200 积分 2021-12-23 加入
Hypertension in China: epidemiology and treatment initiatives
12小时前
已完结
GLP-1 Receptor Agonists Among Patients With Overweight or Obesity, Diabetes, and HFpEF on SGLT2 Inhibitors
1个月前
已完结
Blood pressure‐lowering effects of GLP‐1 receptor agonists exenatide and liraglutide: a meta‐analysis of clinical trials
1个月前
已完结
[Clinical practice guidelines for the management of hypertension in China]
1个月前
已完结
The pathophysiology of hypertension in patients with obesity
1个月前
已关闭
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action
1个月前
已完结
Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study
1个月前
已关闭
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity
1个月前
已完结
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity
1个月前
已完结
Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial
5个月前
已完结
皖公网安备34019202002308
